Cyclacel raises $3M via convertible preferred stock and warrants; cash runway into Q3 2025

Bio Green Med Solution, Inc.

Gross proceeds of $3.0M from sale of 3M shares of Series F Convertible Preferred at $1.00 per share.
Each preferred share converts into 3.27 common shares; conversion requires stockholder approval per Nasdaq rules.
Issued 29.43M warrants (Series A/B/C) at exercise prices $0.51, $0.60, $0.68, all expiring in 5 years.
Net proceeds for working capital; combined with existing cash expected to fund operations into Q3 2025.
Offering sold under Regulation S to non-U.S. accredited investors without a placement agent.

item 3.02item 1.01item 3.03item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.